Sep 04, 2020
The Keratoconus market will be dominated by lenses, cross-linking procedures as well as IVMED-80, if approved in the coming decade. Keratoconus, away from the general perception of a rare disease, has come a long way. Thirty-four years back, in Minnesota, United States, this disease was claimed as rare, which ...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper